Skip to main content
Biomark Diagnostics Inc. logo

Biomark Diagnostics Inc. — Investor Relations & Filings

Ticker · BUX LEI · 529900UHZ378KKXOLY69 CSE Professional, scientific and technical activities
Open in API
Filings indexed 142 across all filing types
Latest filing 2025-05-12 Regulatory Filings
Country CA Canada
Listing CSE BUX

About Biomark Diagnostics Inc.

https://www.biomarkdiagnostics.com/

Biomark Diagnostics Inc. is an oncology-focused company developing advanced liquid biopsy diagnostic technologies for the early detection, monitoring, and screening of cancer. The core technology platform utilizes metabolomics, the study of biomarkers and metabolites, integrated with Artificial Intelligence and Machine Learning algorithms. This approach aims to provide rapid, accurate results for hard-to-detect cancers, thereby improving patient outcomes. The company's pipeline includes the Liquid Biopsy SSAT1 Assay and a Metabolic Panel.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing the publication of a research study in a scientific journal validating a diagnostic test. It does not contain financial results, regulatory form numbers, management changes, or transaction details. It is not an investor presentation or official AGM/annual/interim report. Therefore, it falls into the general fallback category for miscellaneous regulatory announcements (RNS).
2025-05-12 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release announcing that BioMark Diagnostics’ shares have been approved for uplisting to the OTCQB Venture Market. It’s a corporate/regulatory announcement regarding exchange listing status – not a financial results release, not a share issuance nor dividend notice, nor board change, nor M&A, nor an annual or interim report. There is no specific category for uplisting, so it falls into the fallback “Regulatory Filings” category for general regulatory announcements. Therefore, the correct classification is RNS.
2025-05-08 English
Report of exempt distribution (45-106F1).pdf
Capital/Financing Update Classification · 1% confidence The document is a Form 45-106F1 “Report of Exempt Distribution,” which details a private placement of securities – dates, number of units, price, exemptions relied upon, purchasers, proceeds, etc. This is not an annual or quarterly report, dividend notice, or board change; rather it is the statutory filing reporting a capital raise under prospectus exemptions. Therefore it best fits the Capital/Financing Update category.
2025-04-07 English
Material change report - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a Form 51-102F3 Material Change Report filed under Canadian securities rules announcing a non-brokered private placement financing round (9,610,000 units for gross proceeds of $2,883,000). It details the capital raise, warrant terms, hold periods, and use of proceeds. This is clearly an update on company fundraising/financing activity, matching the Capital/Financing Update category (CAP).
2025-03-26 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a standalone certification (Form 52-109FV2) by the CEO certifying the interim financial report and interim MD&A under Canadian NI 52-109 for a venture issuer. It is not the interim report itself (which would be an IR/Quarterly Report) nor an earnings release or management discussion. It serves as a regulatory compliance filing rather than substantive financial content or an announcement of a report. Therefore, it falls into the general “Regulatory Filings” category.
2025-03-01 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV2 “Certification of Interim Filings” under NI 52-109, whereby the CFO certifies the interim financial report and MD&A for the period ended December 31, 2024. It is not the interim financial statements themselves (IR), nor an earnings release (ER), audit report (AR), or board/management announcement (MANG). It also is not a simple “report publication” notice. It is a mandatory regulatory compliance filing without substantive financial data, best fitting the fallback category for miscellaneous regulatory filings (RNS).
2025-03-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.